Historically, European biotechs have concluded few regional licensing deals for Japan. Despite being the second largest pharmaceutical market in the world with sales in excess of $50 billion, the time, distance, language and cultural barriers were considered too challenging. Moreover, companies perceived it was only possible to get decent value if they were licensing potential blockbusters. And they also feared that signing away Japanese rights might jeopardize their chances of attracting Big Pharma, who would want global rights.
But things appear to be changing. While the number of deals is still small—Windhover's Strategic Intelligence Systems Database has tracked...




